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Abstract 
Objective: To evaluate the etiology and 
clinicohematological profile of patients with anemia of 
chronic disease.  
Patients and Method: Patients with anemia of 
chronic disease were included. All underwent bone 
marrow examination, and bone marrow trephine biopsy, 
where required. Etiology was elucidated on the basis of 
clinical history and relevant investigations. Diagnosis of 
anemia of chronic disease was based on increased iron in 
fragments with decreased or absent siderocytes and 
sideroblasts    
Results: Definitive cause of anemia was not ascertained 
in 57.1%. In the rest of the cases tuberculosis (17.1%) was 
the commonest. Majority of the patients (54.3%) were more 
than 60 years of age. Fever (51.4%) was the commonest 
complaint. Severe anemia was found in 25.8%. Bone 
marrow iron stain revealed increased iron in stores with 
absent siderocytes and sideroblasts   
Conclusion: A high number of unexplained cases 
(57.1%) highlights the need to characterize the causes of 
anemia of chronic disease as treatment of underlying 
disease will actually improve the hemoglobin 
concentration in these patients.   
Key words: Anemia, chronic infection, microcytic 
hypochromic blood picture, SLE, tuberculosis, rheumatoid 
arthritis     
Introduction 
Anemia of chronic disease (ACD) is a hypoproliferative 
anemia that develops in response to systemic illness or 
inflammation. It was first described in the 1930s and was 
more fully characterized by Cartwright and Wintrobe in the 
1950s.1 Amongst microcytic hypochromic anemias, ACD is 
the second most prevalent anemia only after iron deficiency. 
Unfortunately, it is commonly under diagnosed in clinical 
practice, and is frequently misunderstood and managed 
inappropriately. Significant gaps remain in comprehension 
of the true prevalence or consequences of ACD. Different 
diseases are found to be associated with ACD. Infections 
(Tuberculosis, bacterial, parasitic, fungal and viral 
infections, including human immunodeficiency virus 
infection), cancers, autoimmune diseases, chronic renal 
diseases and inflammations are most commonly 
incriminated.2  
ACD is characterized by inadequate erythrocyte production 
in the setting of low serum iron, low iron binding capacity, 
low transferrin, but normal or high serum ferritin with a 
preserved or even increased macrophage iron stores in the 
bone marrow, with absence of siderocytes and sideroblasts. 
Iron is very much available in stores but paradoxically is 
unavailable for hemoglobin synthesis (Reticuloendothelial 
block).The erythrocytes are usually normocytic and 
normochromic, but long standing anemia can give rise to 
microcytic and hypochromic blood picture.3-5 
In the pathogenesis of ACD different cytokines play 
important role. Cytokines along with the cells of 
reticuloendothelial system induce changes in iron 
homeostasis, affect the proliferation of erythroid progenitor 
cells, down-regulate erythropoietin production and 
decreases the life span of red cells. All of these then 
contribute to the pathogenesis of anemia. The invasion of 
microorganisms, the emergence of malignant cells or 
autoimmune dyrsregulation leads to activation of T cells 
(CD3+) and monocytes. These cells induce immune effector 
mechanisms, thereby producing cytokines such as 
interferon-γ, tumor necrosis factor-α (TNF-α) and 
interleukin-1. Interkeukin-6 and lipopolysaccharide 
stimulate the hepatic expression of the acute phase protein 
hepcidin, which inhibits duodenal absorption of iron. 
Interferon-γ, lipopolysaccharide, or both increase the 
expression of divalent metal transporter-1 on macrophages 
and stimulate the uptake of ferrous iron (Fe2+). The anti-
inflammatory cytokine interleukin-10 upregulates transferrin 
receptor expression and increases transferrin receptor-
mediated uptake of transferrin-bound iron into monocytes. 
This increased uptake and retention of iron within cells of 
the reticuloendothelial system leads to diversion of iron 
from the circulation into storage sites of the 
reticuloendothelial system, subsequently leading to the 
limitation of availability of iron for erythropoiesis.  
Interferon-γ and lipopolysaccharide down-regulate the 
expression of the macrophage iron transporter ferroprotein-
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1. Ferroportin is a transmembrane exporter of iron, i.e., it is 
responsible for the transfer of absorbed ferrous iron from 
duodenal enterocytes to the circulation. At the same time, 
TNF-α, interleukin-1, interleukin-6 and interleukin-10 
induce ferritin expression and stimulate the storage and 
retention of iron within macrophages. Finally, all these 
mechanisms lead to a decreased iron concentration in the 
circulation and thus to a limited availability of iron for 
erythroid cells. TNF-α, and interferon-γ inhibit the 
production of erythropoietin in the kidney. TNF-α, 
interferon-γ and interleukin-1 directly inhibit the 
differentiation and proliferation of erythroid   progenitor 
cells.6,7     
Identification of hepcidin is an important finding in ACD. 
IL-6, released during inflammatory process, induces 
hepcidin expression. Hepcidin excess causes the endocytosis 
and degradation of the sole known cellular iron exporter, 
Ferroportin, a 12-transmembrane segment protein. 
Ferroportin is found in all tissues that export iron to blood 
plasma. This inhibition and depletion of ferroportin from the 
cellular membranes progressively inhibits iron efflux from 
duodenal eneterocytes, macrophages and other cells 
involved in iron export to erythroid cells.8,9 Another protein 
involved in ACD is lactoferrin. Lactoferrin is similar to 
transferrin, in respect to its size, shape and affinity for 
binding iron. Lactoferrin competes transferrin, get hold of 
the iron and traps it back to macrophages, making it 
unavailable for hemoglobin synthesis.10 Several mechanisms 
independently contribute to ACD. The relative contribution 
of these mechanisms is uncertain. The occurrence of several 
independent processes, each contributing in concert to the 
reduction of hemoglobin, suggests a process of evolutionary 
adaptation.11Patients have microcytic hypochromic or 
normocytic normochromic anemia. Determination of cause 
of anemia holds a significant importance as treatment 
strategies vary with diagnosis. The present study was aimed 
to look into various causes of ACD in patients with anemia 
referred for bone marrow biopsy.     
Patients and Methods 
This retrospective study was conducted in the department of 
pathology, District Head Quarters Hospital, Rawalpindi, 
from January 2010 to December 2011. All the cases 
diagnosed as anemia of chronic disease (n 35) on the basis 
of bone marrow findings and iron staining pattern (increased 
iron in histiocytes with absence of sideroblasts and 
siderocytes) during the study period were included. 
Demographic data (Age, sex), the available clinical data 
(duration of illness, presenting complaints, symptoms, 
history of blood transfusion and provisional diagnosis) and 
blood as well as bone marrow findings were recorded. The 
patients were categorized as having severe anemia (Hb <8.0 
g/dl), moderate anemia (Hb 8.1- 9.5 g/dl) and mild anaemia 
(Hb >9.6/dl and less than 11.0 g/dl in females and <13.0 g/dl 
in males). 
The Giemsa and iron-stained bone marrow smears and H & 
E stained trephine sections, if available, were studied, and 
data were recorded. The data were analyzed for frequencies, 
where ever applicable. 
Results 
Table 1 details the demographic and available clinical & 
laboratory data of our patients. Males comprised 60% of 
cases; male: female ratio was 3: 2. Majority of patients was 
>60years of age. About three fourth of the patients had been 
symptomatic for > 6 months. Fever was a prominent 
symptom in about half of the patients. Anemia was the most 
consistent feature; it was severe (Hb< 8.0 g/dl) in 25.7%, 
and moderate (Hb between 8.1 and 9.5 g/dl) in 45.7% 
patients. Nearly half of the patients had been transfused red 
cell concentrates before they were referred to us. 
 
Table 1: Demographic, clinical and laboratory 
features (n=35)* 
Parameter No (%)
Sex 
Male 
Female    
Age (Yrs) 
18-45 
46-60 
>60 
Duration of Illness (months) 
       <6       
>6  to 12 
       > 12  
History of Fever 
History of Blood Transfusion 
Degree of Anaemia (Hb g/dl) 
       Severe (< 8) 
       Moderate (8 to 9.5) 
       Mild (> 9.5)   
Red Blood Cells Morphology  
Normocytic & Normochromic 
Microcytic & Hypochromic  
Bone Marrow 
Haemophagocytosis 
 
21(60) 
14 (40) 
 
06 (17.1) 
10 (28.6) 
19 (54.3) 
 
09 (25.7) 
18 (51.4) 
08 (22.9) 
18 (51.4) 
17 (48.6) 
 
09 (25.7) 
16 (45.7 ) 
10 (28.6) 
 
23 (65.7) 
12 (34.3) 
 
10 (28.6) 
*All cases showed Increased Iron in bone marrow macrophages 
with absent or decreased siderocytes and sideroblasts 
As shown in table 2, a diagnosis of chronic disease was 
manifest, before bone marrow biopsy was performed, in 
only 15 (42.9%) cases. Tuberculosis was the commonest 
already diagnosed underlying chronic disorder, followed by 
other infections (typhoid, respiratory infections, etc), 
chronic liver disease, systemic lupus erythematosus, and 
chronic renal disease, respectively. 
In the remaining patients (57.1%), who were referred to us 
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for bone marrow biopsy with an attempt to investigate for 
anemia, other cytopenias(s), or fever, the findings indicated 
chronic underlying disorder. In these patients, there was no 
previous clinical suspicion of any chronic disease. Red cell 
morphology was normocytic normochromic in two thirds 
and microcytic hypochromic in the remaining one third of 
the cases. On bone marrow smears, iron overload with 
absence of siderocytes and sideroblasts & siderocytes was a 
consistent feature; haemophagocytosis was a prominent 
feature in 28.6% of cases. 
  Table 2: Anaemia of Chronic Diseases-Causes (n 35) 
Cause No (%)
Tuberculosis 
Chronic Liver Disease 
Systemic Lupus Erythrmatosus 
Typhoid 
Chronic Renal failure 
Chronic Infections 
No Chronic disease suspected 
before bone marrow biopsy 
6 (17.1) 
3 ( 8.6) 
2 (5.7) 
1 (2.9) 
1 (2.9) 
2 (5.7) 
20 (57.1) 
Discussion 
ACD is a hypoproliferative anemia that accompanies 
chronic inflammatory, infectious, or neoplastic disorders. 
The anemia of chronic disease is primarily an anemia due to 
underproduction of red cells, with low reticulocyte 
production, and is most often a normochromic, normocytic 
anemia. However, in 30% to 50% of patients, the red cells 
are hypochromic and microcytic and, most often, the serum 
iron, total iron-binding capacity, and transferrin saturation 
are reduced in the presence of adequate iron stores.12  
In comprehensive population-based studies, precise 
estimates of prevalence are difficult to ascertain because 
many patients with anemia are not investigated sufficiently 
to establish the cause. Moreover, no consensus research 
criteria exist for the diagnosis of anemia of chronic disease, 
and patients may have multifactorial causes for anemia, 
wherein ACD is only a part.10 According to the World 
Health Organization (WHO) mild anemia corresponds to a 
Hb 9.5 g/dl, moderate anemia to a Hb 8 g/dl but <9.5 g/dl, 
and severe anemia to a Hb <8.0 g/dl. Anemia of chronic 
disease is usually patients have mild to moderate.13 Our 
results also showed that most of patients diagnosed as ACD 
(74.5%) had mild to moderate degree of anemia. Majority of 
our patients (54%) were more than 60 years age. This is also 
important because such patients do not respond to treatment 
unless underlying disease is diagnosed and treated. Bone 
marrow examination also differentiates these cases of ACD 
from refractory anemia (MDS) which is suspected in elderly  
patients not responding to treatment.  
In 57% of our cases there was no definitive diagnosis of an 
underlying disease was evident. They were referred for bone 
marrow biopsy to evaluate the cause of anemia and showed 
iron staining pattern of underlying disorder. It is important 
to investigate these patients for an underlying pathology. 
There were 6 cases of tuberculosis in our cases showing iron 
staining pattern of anemia of chronic disease. Multiple 
causes of anemia in tuberculosis have been identified. These 
include iron deficiency, folate deficiency (most probably 
because of drug therapy) decreased red cell life span, 
depressed erythropoiesis and defective ferrokinetics.14 In 
this regard it is particularly important to differentiate anemia 
due to iron deficiency from that of ACD. Various tests 
differentiate iron deficiency anemia from ACD. These 
include serum iron, TIBC, Transferrin saturation, serum 
ferritin, serum transferrin receptors and red cell zinc 
protoporphyrin. However determination of iron stores by 
bone marrow examination remains the best method for 
assessment of iron stores.15 Other tests include CRP and 
ESR (both braised in ACD). TB-associated anemia is 
usually mild and resolves with anti-TB treatment.16 There 
were 2 diagnosed cases of SLE showing iron staining 
pattern of underlying disorder. Hematological abnormalities 
are very common in systemic lupus erythematosus. Αnemia 
is found in approximately 50% of patients, with anemia of 
chronic disease being the most common form. Other 
mechanisms contributing to development of anemia in SLE 
include renal insufficiency, blood loss, dietary insufficiency, 
medications, hemolysis, infection, hypersplenism, 
myelofibrosis, myelodysplasia, and aplastic anemia 
(probably having an autoimmune pathogenesis).17 In the 
absence of either symptom attributable to anemia, anemia of 
chronic inflammation does not require specific treatment 
(provided other causes mentioned above are ruled out). 
Some of the patients of SLE show improvement in 
hemoglobin concentration when treated with rEPO 
(Recombinant erythropoietin) ACD is considered the most 
frequent cause of anemia in RA; however, iron deficiency 
due to gastrointestinal blood loss or a combination of both. 
It is important to determine the cause of anemia in order to 
treat these patients. The most reliable characteristic for the 
detection of iron deficiency is stainable iron content in bone 
marrow aspirate. Significant increase in hemoglobin 
concentration in these patients has been observed in patients 
of Rheumatoid arthritis treated with erythropoietin.18 
Similarly in celiac disease though major cause for anemia in 
deficiency of B12, Folic acid and iron, but it has been 
observed that in different studies ACD affects a significant 
portion of celiac disease patients at presentation, 
contributing to significant number of cases and the response 
of anemic patients to a gluten-free diet was not influenced 
by the presence of ACD.19 This has also been observed that 
mean serum levels of inflammatory cytokines that contribute 
to ACD, including interleukin- 1b, interleukin-6, tumor 
necrosis factor-a, and interferon-g, are increased in active 
celiac disease.20,21   
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Anemia is a common association of malignant disease and 
may affect treatment decisions. It is important to recognize 
the factors leading to development of anemia and to exclude 
those that are treatable. The recognition that tumor-
associated cytokine production is a major factor in the 
anemia of malignancy, and rEPO can overcome this 
suppression.22  
ACD, if marked, can be a reflection of more progressive 
underlying disease. Treatment of underlying disease is the 
therapeutic approach of choice for ACD. Treatment with 
iron therapy is contraindicated in ACD. In general iron 
therapy should only be considered if there is concomitant 
iron deficiency and this should be with oral iron therapy. 
Treatment with parenteral iron therapy should be avoided 
due to possible aggravation of infection by large bolus of 
infection. Blood transfusions are helpful in the context of 
severe life threatening anemia. Although the positive short 
term effects of therapy with erythropoietic agents on the 
correction of anemia and avoidance of blood transfusion are 
well documented, few data are available on possible effects 
on the course of disease. The therapeutic effects of these 
agents primarily include the stimulation of iron uptake and 
heme biosynthesis in erythroid cells. Additionally they can 
counter act the antiproliferative effects of cytokines. The 
pivotal role of hepcidin in iron metabolism and in the 
pathogenesis of ACD could lead to development of 
inhibitors of hepcidin for clinical use. Future strategies, to 
treat ACD, may thus include the use of these inhibitors and 
iron-chelation therapy to induce the endogenous antagonists 
that overcome the retention of iron within the 
reticuloendothelial system, and hormones or cytokines that 
might effectively stimulate erythropoiesis under 
inflammatory conditions.23-25 It is thus very important to 
determine the cause of anemia in various chronic 
inflammatory conditions as this would affect the treatment 
outcome and quality of life in these patients.  
 
Conclusions 
A high number of unexplained cases (57.1%) highlights the 
need to characterize the causes of anemia of chronic disease 
as treatment of underlying disease will actually improve the 
hemoglobin concentration in these patients.   
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